RxDoctor Payments Data

William Fleet, MD

Cardiovascular Disease · Franklin, TNNPI 1952304990

Payments from drug & device makers

$2,526in general payments, 2019–2025

Across 129 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$634
  • Boehringer Ingelheim$389
  • Novartis$264
  • E.r. Squibb & Sons, L.L.C.$217
  • Esperion Therapeutics, Inc.$188
  • Heartflow, Inc.$130
  • plus $703 from 14 others

What the payments were for

  • Food & beverage$2,526100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,526 in reported general payments places this provider in the 50th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$187,845
Medicare patients
995
Services billed
2,968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban743$676,574
XareltoRivaroxaban80$80,770
EntrestoSacubitril/Valsartan88$74,487
Repatha SureclickEvolocumab74$56,084
Nebivolol Hcl288$20,532
JardianceEmpagliflozin11$14,100
Metoprolol Succinate653$9,961
Atorvastatin Calcium555$6,222
Ranolazine ErRanolazine47$6,169
Flecainide Acetate100$5,614
Valsartan124$5,389
Bisoprolol Fumarate153$5,200
Dabigatran EtexilateDabigatran Etexilate Mesylate21$5,127
Rosuvastatin Calcium321$4,977
Diltiazem 24hr Er (Cd)Diltiazem Hcl147$4,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$676,574743 claims
Johnson & JohnsonXarelto$102$80,77080 claims
NovartisEntresto$264$74,48788 claims
Boehringer IngelheimJardiance$389$14,10011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 429 cardiovascular disease providers in Tennessee.

Other cardiovascular disease in Franklin

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →